Q-omics provides the consensus-scored RAP1BP3 profile across patient tissues and cancer cell-line models. RAP1BP3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RAP1BP3 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, RAP1BP3 RNA expression shows 8,234 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, HNSC, and LSCC as cancer lineages where RAP1BP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP1BP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP1BP3 survival associations across molecular data types. RAP1BP3 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP1BP3 RNA expression–survival associations across cancer types. High RAP1BP3 expression shows unfavorable associations in STAD, ESCA, SARC, KIRC, LGG and DLBC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for RAP1BP3 RNA expression.
This table summarizes RAP1BP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RAP1BP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP1BP3 shows lower tumor expression in LUAD and higher tumor expression in HNSC, BLCA and KIRP. The HNSC box plot shows higher RAP1BP3 RNA expression in tumor versus normal tissue (log2 FC = +0.065, t-test p = .009).
This table shows molecular features associated with RAP1BP3 in patient tissues and cancer cell lines. In patient samples, RAP1BP3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
